" Bruce Wiseman, the U.S. President of CCHR says, "........However, people are waking up to the fact that psychiatric 'mental disorders' have absolutely no scientific/medical validity and that psychiatrists falsely portray them as a disease or physical condition to convince teachers and parents that these are medical issues, which is a complete fraud. ........"
Many of us who have been adversly affected by prescription medications have spent years trying to regain our credibility with a medical profession who have chosen and continue to take the 'head buried in sand' stance - leaving us the patients with disabilities and health problems unrecognised - unacknowledged and untreated -
The drug safety authorities and governments choose to release these drugs on an unsuspecting and trusting public - The medical profession have been seduced by the drug reps into believing that the drugs being offered are safe --despite an increasing amount of evidence being proffered by experts - survivors and victims relatives to the contrary-- and in this instance their Hippocratic oath seems of little value or meaning -
In some instances the very 'professionals' who proffered those drugs as a way of helping - healing and curing us - have called us mentally ill for beleiving the drugs were the cause of our health problems and 'delusional' for beleiving that our health has improved since stopping medication and using in their place nutritional supplements to heal and repair the damage they caused -
Their reasoning behind this name calling - that our belief was not based on scientific facts - yet it is scientific fact in it's own right that if a human body is not given sufficient and needed nutrition it will wither and die - <br />
Yet those very same professionals believe that their treatments and drugs work - But their treatments have no basis in scientific fact - There are NO studies that prove that these treatments work or are safe - So are they delusional for their beliefs ??
Or are they like so many - the 'Ad Mans Dream' ? Having been sucked in by the propaganda the drugs companies pay PR companies handsomly to generate ??
Not such a bad thing if your usurped into changing your brand of washing up liquid - after all no-ones life depends it !!!
http://www.network54.com/Forum/message?forumid=281849&messageid=1105317931
"The changing competitive landscape
Response to Commercial Insight: Antipsychotics - From Blockbuster Brands to Billion Dollar Generics
The changing competitive landscape
The Central Nervous System (CNS) pharmaceutical markets have been led by a number of blockbuster products in recent history, and the short- to mid-term future will see a number of key patent expiries. This situation, together with continued unmet medical needs and an increasing consumer and regulatory focus on side effects, necessitates a new generation of innovation and strategic marketing to maintain 'branded' control of the market and blockbuster potentials. The requirement for innovation is opening a market, normally dominated by the major pharma players, to smaller biotech companies, creating a market where partnership opportunities abound.
Key issues
Our research answers your key questions regarding the following issues:
• What's in the pipeline for specific therapy areas?
• How successful will pipeline launches be?
• What gaps exist in CNS pipeline development?
• What are the relative market sizes within CNS?
• Which secondary indications will provide potential for marketed products?
• How do physicians segment their patients?
• Which segments offer commercial potential?
• Who are the key players in influencing prescribing choice?
• How are key players effectively targeted?
Datamonitor’s expertise
Datamonitor's CNS Strategic Planning Program (SPP) offers research, analysis and advisory services that provide an understanding of the competitive landscape to support informed strategic decision-making in your company.
Targeting Innovation – Significant unmet medical need remains in many CNS disorders. Our analysts draw on primary research with physicians, opinion leaders and patient groups, in addition to attendance at scientific congresses and secondary research, to define potential revenue-producing avenues of innovation. Currently marketed and pipeline therapies are reviewed against these criteria to produce a gap analysis, providing an assessment of available target opportunities.
Brand Positioning – As prescribers see increasing homogeneity between products, defining and owning your target segment becomes more difficult. Datamonitor's primary research into physician perception and brand positioning is the basis for our expert analysis and recommendations on key marketing messages that are fundamental to maximizing return.
Regulatory Restriction – The success of licensing, launch strategies, marketing and lifecycle management is dependent on the regional regulatory environment. Datamonitor’s analysis provides advice on country-by-country regulatory issues and assesses the
impact of previous strategies via case studies.
Market Maturity – As a market matures, brands need to be implementing marketing strategies to ensure brand loyalty, providing differentiation and buoyancy in the face of generic competition. With SSRIs, novel anticonvulsants and atypical antipsychotics seeing generic entrants over the next few years, novel drugs and current therapies must look to new strategies and licenses to ensure success. Datamonitor CNS analysts evaluate a number of such approaches in our commercial insights reports.
BUT is it the Psychiatrists ?? or the Drugs Companies ?? who are behind the invent a drug invent an illness to use it for - and how do they do this - they employ PR companies - "